



FORM PTO-1449/A and B (modified PTO/SB-08)

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

SEP 11 2006

APPLICATION NO.: 10/534,348

ATTY. DOCKET NO.: A0848.70005US00

FILING DATE: May 9, 2005

CONFIRMATION NO.: 4929

APPLICANT: Silence et al.

GROUP ART UNIT: 1649

EXAMINER: Gregory S. Emch

Sheet 1 of 2

Sheet 1 of 2

**U.S. PATENT DOCUMENTS**

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A1	5,976,532		Coller et al.	11-02-1999
	A2	6,419,934	B1	Tobinick	07-16-2002
	A3	6,759,518	B1	Kontermann et al.	07-06-2004
	A4	2002-0054878	A1	Lowe et al.	05-09-2002
	A5	2003-0092892	A2	Frenken et al.	05-15-2003
	A6	2006-0034833	A1	Silence et al.	02-16-2006
	A7	2006-0115470	A1	Silence et al.	06-01-2006

**FOREIGN PATENT DOCUMENTS**

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
	B1	EP	0 589 840	A1	CIBA Geigy AD; Tanox Biosystems, Inc.	03-30-1994	
	B2	EP	0 952 218	A2	Hoeschst Marion Roussel De GMBH	10-27-1999	
	B3	EP	1 002 861	A1	Unilever PLC	05-24-2000	
	B4	WO	90/10707	A1	Meide Petrus Hendrikus VD	09-20-1990	
	B5	WO	91/02078	A1	Peptide Technology Ltd.	02-21-1991	
	B6	WO	92/01787	A1	Cambridge Antibody Technology Ltd.	02-06-1992	
	B7	WO	94/04678	A1	Casterman	03-03-1994	
	B8	WO	99/09055	A2	Innogenetics N.V.	02-25-1999	
	B9	WO	99/23221	A2	Unilever PLC	05-14-1999	
	B10	WO	02/051351	A1	K.U.Leuven Research and Development	07-04-2002	
	B11	WO	02/057445	A1	National Research Council of Canada	07-25-2002	
	B12	WO	02/079781	A1	Heska Corporation	10-10-2002	
	B13	WO	2004/041862	A2	Ablynx N.V.	05-21-2004	
	B14	WO	2004/041863	A2	Ablynx N.V.	05-21-2004	
	B15	WO	2004/041865	A2	Ablynx N.V.	05-21-2004	
	B16	WO	2004/041867	A2	Ablynx N.V.	05-21-2004	

EXAMINER:

DATE CONSIDERED:

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

922045.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./

O I P E  
SEP 11 2006

FORM PTO-449/A and B (modified) PTO/SB/08

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

APPLICATION NO.:	10/534,348	ATTY. DOCKET NO.:	A0848.70005US00
FILING DATE:	May 9, 2005	CONFIRMATION NO.:	4929
APPLICANT:	Silence et al.		
GROUP ART UNIT:	1649	EXAMINER:	Gregory S. Emch

Sheet 2 of 2

## OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
-	C1	ARBABI GHARROUDI et al., Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. <i>FEBS Lett.</i> 1997 Sep 15;414(3):521-6.	
-	C2	CORTEZ-RETAMOZO et al., Efficient tumor targeting by single-domain antibody fragments of camels. <i>Int J Cancer.</i> 2002 Mar 20;98(3):456-62.	
-	C3	DAVIES et al., Antibody VH domains as small recognition units. <i>Biotechnology (N Y).</i> 1995 May;13(5):475-9.	
-	C4	DESMYTER et al., Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. <i>J Biol Chem.</i> 2001 Jul 13;276(28):26285-90.	
-	C5	D'HAENS et al., Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. <i>Gastroenterology.</i> 1999 May;116(5):1029-34.	
-	C6	ELS CONRATH et al., Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. <i>J Biol Chem.</i> 2001 Mar 9;276(10):7346-50.	
-	C8	HARMSSEN et al., Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. <i>Mol Immunol.</i> 2000 Aug;37(10):579-90.	
-	C8	MALLENDER et al., Construction, expression, and activity of a bivalent bispecific single-chain antibody. <i>J Biol Chem.</i> 1994 Jan 7;269(1):199-206.	
-	C8	MUYLDERMANS et al., Single domain camel antibodies: current status. <i>J Biotechnol.</i> 2001 Jun;74(4):277-302.	
-	C10	ROTE et al., Antithrombotic effects of DMP 728, a platelet GPIIb/IIIa receptor antagonist, in a canine model of arterial thrombosis. <i>J Cardiovasc Pharmacol.</i> 1994 Apr;23(4):681-9.	
-	C11	SAELMAN et al., Platelet adhesion to collagen types I through VIII under conditions of stasis and flow is mediated by GPIa/IIa (alpha 2 beta 1-integrin). <i>Blood.</i> 1994 Mar 1;83(5):1244-50.	
-	C12	TANHA et al., Selection by phage display of llama conventional V(H) fragments with heavy chain antibody V(H)H properties. <i>J Immunol Methods.</i> 2002 May 1;263(1-2):97-109.	
-	C13	VALLE et al., Infliximab. <i>Expert Opin Pharmacother.</i> 2001 Jun;2(6):1015-25.	
-	C14	WARD et al., Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. <i>Nature.</i> 1989 Oct 12;341(6242):544-6.	
-			
-			

\*A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_, filed \_\_\_, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an IDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

EXAMINER:	/Gregory Emch/	DATE CONSIDERED:	11/25/2008
-----------	----------------	------------------	------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

922045.1

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /G.E./